Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have demonstrated significant benefits to patients with non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations; however, acquired resistance limits their long-term efficacy. Therefore, it remains an urgent requ...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yingjie, Bian, Dongliang, Zhang, Xuelin, Zhang, Huibiao, Zhu, Zhenghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705995/
https://www.ncbi.nlm.nih.gov/pubmed/33200796
http://dx.doi.org/10.3892/mmr.2020.11686

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705995/
https://www.ncbi.nlm.nih.gov/pubmed/33200796
http://dx.doi.org/10.3892/mmr.2020.11686

Ejemplares similares